Aspira Women’s Health, Inc. to Participate in BTIG’s Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Rhea-AI Summary

Aspira Women's Health, Inc. (Nasdaq: AWH) announced its participation in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference happening from February 17-19. The company will present on February 18 at 9:30 am Eastern Time. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment. Their product portfolio includes FDA-cleared tests like OVA1® and OVERA®, and they aim to address ethnic disparities in health outcomes. For more details, visit www.aspirawh.com.

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate and present in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference taking place on February 17-19. Details for the event are below:

BTIG MedTech, Digital Health, Life Science and Diagnostic Tools Conference Presentation:
Date: Time: Webcast:	Thursday, February 18, 2021 9:30 am Eastern Time https://wsw.com/webcast/btig3/awh/1583008

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as Vermillion Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1^® and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASight^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

When is Aspira Women's Health presenting at the BTIG Conference?

Aspira Women's Health will present on February 18, 2021, at 9:30 am Eastern Time.

What is the focus of Aspira Women's Health's presentation?

The presentation will likely focus on innovative testing solutions for women's health and ovarian cancer risk assessment.

Where can I watch Aspira Women's Health's presentation?

You can watch the presentation via webcast at https://wsw.com/webcast/btig3/awh/1583008.

What are some products offered by Aspira Women's Health?

Aspira offers products like OVA1® and OVERA® for ovarian malignancy risk detection.

What is the significance of the BTIG Conference for Aspira Women's Health?

The BTIG Conference provides a platform for Aspira to showcase its advancements and innovations in women's health.